Final report of the phase I trial of the hypoxic cell radiosensitizer SR 2508 (etanidazole) Radiation Therapy Oncology Group 83-03.

[1]  C. Coleman,et al.  Effects of nitroimidazoles on neuronal cells in vitro. , 1989, International Journal of Radiation Oncology, Biology, Physics.

[2]  C. Coleman,et al.  Initial results of a phase I trial of continuous infusion SR 2508 (etanidazole): a radiation therapy oncology group study. , 1989, International journal of radiation oncology, biology, physics.

[3]  C. Coleman,et al.  Enhancement of the clinical activity of melphalan by the hypoxic cell sensitizer misonidazole. , 1988, Cancer research.

[4]  C. Coleman,et al.  Hypoxia in tumors: a paradigm for the approach to biochemical and physiologic heterogeneity. , 1988, Journal of the National Cancer Institute.

[5]  C. Coleman,et al.  Chemical modifiers of cancer treatment. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  D. Trump,et al.  Clinical chemosensitization by misonidazole and related compounds: a critical evaluation. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  C. Coleman,et al.  Relationship between the neurotoxicity of the hypoxic cell radiosensitizer SR 2508 and the pharmacokinetic profile. , 1987, Cancer research.

[8]  N. Bleehen,et al.  A phase I study of the combination of two hypoxic cell radiosensitizers, Ro 03-8799 and SR-2508: toxicity and pharmacokinetics. , 1986, International journal of radiation oncology, biology, physics.

[9]  C. Coleman,et al.  Phase I trial of the hypoxic cell radiosensitizer SR-2508: the results of the five to six week drug schedule. , 1986, International journal of radiation oncology, biology, physics.

[10]  J. Fowler,et al.  Eighth annual Juan del Regato lecture. Chemical modifiers of radiosensitivity--theory and reality: a review. , 1985, International journal of radiation oncology, biology, physics.

[11]  C. Coleman,et al.  Hypoxic cell radiosensitizers: expectations and progress in drug development. , 1985, International journal of radiation oncology, biology, physics.

[12]  S. Dische.  Chemical sensitizers for hypoxic cells: a decade of experience in clinical radiotherapy. , 1985, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[13]  C. Coleman,et al.  Initial report of the phase I trial of the hypoxic cell radiosensitizer SR-2508. , 1984, International journal of radiation oncology, biology, physics.

[14]  J. Brown,et al.  Clinical trials of radiosensitizers: what should we expect? , 1984, International journal of radiation oncology, biology, physics.

[15]  J. Denekamp,et al.  The potential benefit from a perfect radiosensitizer and its dependence on reoxygenation. , 1982, The British journal of radiology.

[16]  D. M. Brown,et al.  SR-2508: a 2-nitroimidazole amide which should be superior to misonidazole as a radiosensitizer for clinical use. , 1981, International journal of radiation oncology, biology, physics.

[17]  J. Fowler,et al.  Misonidazole in fractionated radiotherapy: are many small fractions best? , 1980, The British journal of radiology.

[18]  L. H. Gray,et al.  The Histological Structure of Some Human Lung Cancers and the Possible Implications for Radiotherapy , 1955, British Journal of Cancer.